Decensi A - Search Results

1

Effect of fenretinide on plasma IGF-I and IGFBP-3 in early breast cancer patients.

Torrisi R, Parodi S, Fontana V, Pensa F, Casella C, Barreca A, De Palo G, Costa A, Decensi A. Torrisi R, et al. Among authors: decensi a. Int J Cancer. 1998 Jun 10;76(6):787-90. doi: 10.1002/(sici)1097-0215(19980610)76:6<787::aid-ijc3>3.0.co;2-u. Int J Cancer. 1998. PMID: 9626341

2

Activity of 4-HPR in superficial bladder cancer using DNA flow cytometry as an intermediate endpoint.

Decensi A, Bruno S, Giaretti W, Torrisi R, Curotto A, Gatteschi B, Geido E, Polizzi A, Costantini M, Bruzzi P, et al. Decensi A, et al. J Cell Biochem Suppl. 1992;16I:139-47. doi: 10.1002/jcb.240501327. J Cell Biochem Suppl. 1992. PMID: 1305678 Clinical Trial.

3

Phase II study of tamoxifen and high-dose retinyl acetate in patients with advanced breast cancer.

Boccardo F, Canobbio L, Resasco M, Decensi AU, Pastorino G, Brema F. Boccardo F, et al. Among authors: decensi au. J Cancer Res Clin Oncol. 1990;116(5):503-6. doi: 10.1007/BF01613002. J Cancer Res Clin Oncol. 1990. PMID: 2229142 Clinical Trial.

4

The metabolite N-4-methoxyphenylretinamide is a major determinant of fenretinide induced decline of plasma insulin-like growth factor-1.

Torrisi R, Pensa F, Fontana V, Costa A, Decensi A. Torrisi R, et al. Among authors: decensi a. Eur J Cancer. 1995;31A(3):420-1. doi: 10.1016/0959-8049(94)00524-9. Eur J Cancer. 1995. PMID: 7786612 No abstract available.

5

Differential effects of N-(4-hydroxyphenyl)retinamide and retinoic acid on neuroblastoma cells: apoptosis versus differentiation.

Ponzoni M, Bocca P, Chiesa V, Decensi A, Pistoia V, Raffaghello L, Rozzo C, Montaldo PG. Ponzoni M, et al. Among authors: decensi a. Cancer Res. 1995 Feb 15;55(4):853-61. Cancer Res. 1995. PMID: 7850799

6

Pilot study of high dose fenretinide and vitamin A supplementation in bladder cancer.

Decensi A, Bruno S, Torrisi R, Parodi S, Polizzi A. Decensi A, et al. Eur J Cancer. 1994;30A(12):1909-10. doi: 10.1016/0959-8049(94)00336-4. Eur J Cancer. 1994. PMID: 7880629 Clinical Trial. No abstract available.

7

DNA flow cytometry as a surrogate end-point in patients with superficial bladder cancer treated with 4-HPR.

Decensi A, Curotto A, Bruno S, Costantini M, Torrisi R, Gatteschi B, Cussotto M, Pizzorno R, Quattrini S, Repetto U, et al. Decensi A, et al. Eur J Cancer Prev. 1994 Jul;3(4):377-9. doi: 10.1097/00008469-199407000-00017. Eur J Cancer Prev. 1994. PMID: 7950899 Clinical Trial. No abstract available.

8

Factors affecting plasma retinol decline during long-term administration of the synthetic retinoid fenretinide in breast cancer patients.

Torrisi R, Parodi S, Fontana V, Rondanina G, Formelli F, Costa A, Boccardo F, Decensi A. Torrisi R, et al. Among authors: decensi a. Cancer Epidemiol Biomarkers Prev. 1994 Sep;3(6):507-10. Cancer Epidemiol Biomarkers Prev. 1994. PMID: 8000302

9

Breast cancer chemoprevention: studies with 4-HPR alone and in combination with tamoxifen using circulating growth factors as potential surrogate endpoints.

Decensi A, Formelli F, Torrisi R, Costa A. Decensi A, et al. J Cell Biochem Suppl. 1993;17G:226-33. doi: 10.1002/jcb.240531142. J Cell Biochem Suppl. 1993. PMID: 8007703 Clinical Trial.

10

Stimulation of erythropoiesis by the non-steroidal anti-androgen nilutamide in men with prostate cancer: evidence for an agonistic effect?

Decensi A, Torrisi R, Fontana V. Decensi A, et al. Br J Cancer. 1994 Mar;69(3):617-9. doi: 10.1038/bjc.1994.115. Br J Cancer. 1994. PMID: 8123500 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

273 results

Search Page

Filters